ATE455793T1 - Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen - Google Patents

Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Info

Publication number
ATE455793T1
ATE455793T1 AT02721722T AT02721722T ATE455793T1 AT E455793 T1 ATE455793 T1 AT E455793T1 AT 02721722 T AT02721722 T AT 02721722T AT 02721722 T AT02721722 T AT 02721722T AT E455793 T1 ATE455793 T1 AT E455793T1
Authority
AT
Austria
Prior art keywords
meningococcal
epitopes
monoclonal antibodies
molecular mimetics
antibodies against
Prior art date
Application number
AT02721722T
Other languages
German (de)
English (en)
Inventor
Dan Granoff
Gregory Moe
Rino Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Childrens Hosp Oak Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Childrens Hosp Oak Res Inst filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE455793T1 publication Critical patent/ATE455793T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02721722T 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen ATE455793T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28455401P 2001-04-17 2001-04-17
US32683801P 2001-10-03 2001-10-03
PCT/US2002/011501 WO2002083711A2 (en) 2001-04-17 2002-04-11 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies

Publications (1)

Publication Number Publication Date
ATE455793T1 true ATE455793T1 (de) 2010-02-15

Family

ID=26962673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721722T ATE455793T1 (de) 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Country Status (10)

Country Link
US (1) US7534444B2 (enExample)
EP (1) EP1379272B1 (enExample)
JP (3) JP2004529643A (enExample)
CN (1) CN1306956C (enExample)
AT (1) ATE455793T1 (enExample)
AU (1) AU2002252638A1 (enExample)
CA (1) CA2439428C (enExample)
DE (1) DE60235155D1 (enExample)
RU (1) RU2322451C2 (enExample)
WO (1) WO2002083711A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
WO2002020059A2 (en) * 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2005023295A2 (en) * 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
CA2555342A1 (en) * 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
DE102004023906A1 (de) * 2004-05-13 2005-12-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von chemischen Mikroarrays
CN105315347A (zh) 2005-11-30 2016-02-10 株式会社癌免疫研究所 新型肽化合物
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US10527329B2 (en) 2008-04-18 2020-01-07 Denso Corporation Ejector-type refrigeration cycle device
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2823312B1 (en) * 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPH0720878B2 (ja) 1983-11-21 1995-03-08 ザ ウエルカム フアウンデ−シヨン リミテツド 改善された複合体、それらの製造法および該複合体を含有する製剤
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
US5128460A (en) * 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
HU9201966D0 (en) 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
RU2068270C1 (ru) * 1993-01-13 1996-10-27 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Антиген менингококков группы в
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
EP0939647B2 (en) 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
EP1007546B1 (en) 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molecular mimetics of meningococcal b epitopes
NZ532665A (en) * 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
JP4812942B2 (ja) 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
DK1228217T3 (da) * 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
BR0010361A (pt) * 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
DE60144353D1 (de) * 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine

Also Published As

Publication number Publication date
CN1602204A (zh) 2005-03-30
JP2008259503A (ja) 2008-10-30
JP2010011868A (ja) 2010-01-21
CN1306956C (zh) 2007-03-28
US7534444B2 (en) 2009-05-19
WO2002083711A2 (en) 2002-10-24
DE60235155D1 (de) 2010-03-11
RU2322451C2 (ru) 2008-04-20
JP2004529643A (ja) 2004-09-30
RU2003133300A (ru) 2005-04-20
EP1379272A4 (en) 2005-12-14
CA2439428C (en) 2012-01-24
EP1379272B1 (en) 2010-01-20
EP1379272A2 (en) 2004-01-14
US20040013686A1 (en) 2004-01-22
AU2002252638A1 (en) 2002-10-28
CA2439428A1 (en) 2002-10-24
JP5215275B2 (ja) 2013-06-19
WO2002083711A3 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
ATE455793T1 (de) Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
GEP20053691B (en) Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
EP2277537A3 (en) Neisseria meningitidis conjugate combination vaccine
ATE505478T1 (de) Molekular-mimetika von meningokokkalen b epitopen
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
JP2007533729A5 (enExample)
BR0015961A (pt) Antìgeno de neisseria de 85kda
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
MA30065B1 (fr) Vaccin
GB0406013D0 (en) Analysis of saccharide vaccines without interference
LU92241I2 (fr) Combinaison de la protéine de fusion NHBA du groupe B de Neisseria meningitidis et de la protéine defusion fHbp du groupe B de Neisseria meningitidis
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
BR9906927A (pt) Proteìnas de neisseria meningitidis
FR17C1042I2 (fr) Nouvelles compositions immunogenes pour la prevention et le traitement de la meningite a meningocoques
DK1587537T3 (da) Injicerbare vacciner mod multiple meningococ-serogrupper
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
BR0012424A (pt) Peptìdeos meningocócicos antigênicos
Plested et al. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B
MA29459B1 (fr) Vaccins
NO902280L (no) Ny poroes farmasoeytisk form og fremstilling derav.
DE60207278D1 (de) Attenuierte bakterien verwendbar als impstoffe
ATE375514T1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
BRPI0500090A (pt) Composição de acabamento
ATE471156T1 (de) Antigene zusammensetzungen zur immunisierung nichtmenschlicher säuger gegen streptococcus equi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties